Pre-made Nipocalimab benchmark antibody ( Whole mAb, anti-FCGRT therapeutic antibody, Anti-FCRN/FcgammaRn/alpha-chain Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Nipocalimab biosimilar, Whole mAb, Anti-FCGRT Antibody: Anti-FCRN/FcgammaRn/alpha-chain therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Nipocalimab is a fully human, aglycosylated, effectorless immunoglobulin G1 (IgG) anti-FcRN antibody that functions to reduce the levels of other IgG antibodies in the blood, including the autoantibodies that cause gMG.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-378-1mg	1mg	3090
GMP-Bios-ab-378-10mg	10mg	Inquiry
GMP-Bios-ab-378-100mg	100mg	Inquiry
GMP-Bios-ab-378-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Nipocalimab biosimilar, Whole mAb, Anti-FCGRT Antibody: Anti-FCRN/FcgammaRn/alpha-chain therapeutic antibody
INN Name	Nipocalimab
Target	FCGRT
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	5whk:HL/5whj:HL
Year Proposed	2019
Year Recommended	2020
Companies	Momenta
Conditions Approved	na
Conditions Active	Autoimmune haemolytic anaemia;Haemolytic disease of newborn;Myasthenia gravis
Conditions Discontinued	na
Development Tech	na